MCID: WLM005
MIFTS: 24

Wilms Tumor 2

Categories: Genetic diseases, Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Wilms Tumor 2

MalaCards integrated aliases for Wilms Tumor 2:

Name: Wilms Tumor 2 54 29 13 69

Characteristics:

OMIM:

54
Miscellaneous:
most case are sporadic

Inheritance:
somatic mutation
autosomal dominant


HPO:

32

Classifications:



External Ids:

OMIM 54 194071

Summaries for Wilms Tumor 2

MalaCards based summary : Wilms Tumor 2 is related to familial wilms tumor 2 and influenza, severe, and has symptoms including nephroblastoma An important gene associated with Wilms Tumor 2 is H19 (H19, Imprinted Maternally Expressed Transcript (Non-Protein Coding)). The drugs Azacitidine and Decitabine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone.

Description from OMIM: 194071

Related Diseases for Wilms Tumor 2

Diseases in the Familial Wilms Tumor family:

Wilms Tumor 6 Wilms Tumor 2
Hereditary Wilms' Tumor Familial Wilms Tumor 2

Diseases related to Wilms Tumor 2 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 familial wilms tumor 2 11.9
2 influenza, severe 8.9 H19 KCNQ1DN WT2

Symptoms & Phenotypes for Wilms Tumor 2

Symptoms via clinical synopsis from OMIM:

54

Neoplasia:
nephroblastoma (wilms tumor)

Genitourinary- Kidneys:
nephroblastoma (wilms tumor)


Clinical features from OMIM:

194071

Human phenotypes related to Wilms Tumor 2:

32
id Description HPO Frequency HPO Source Accession
1 nephroblastoma 32 HP:0002667

Drugs & Therapeutics for Wilms Tumor 2

Drugs for Wilms Tumor 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 230)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 1 320-67-2 9444
2
Decitabine Approved, Investigational Phase 2, Phase 3 2353-33-5 451668
3
Cytarabine Approved, Investigational Phase 2, Phase 3, Phase 1 147-94-4 6253
4
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
5
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
6
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
9
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
11
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
12
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
13
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
14
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
15
Morphine Approved, Investigational Phase 3 57-27-2 5288826
16
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
17
Mycophenolic acid Approved Phase 3 24280-93-1 446541
18
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
19
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
20 Antimetabolites Phase 2, Phase 3, Phase 1
21 Antimetabolites, Antineoplastic Phase 2, Phase 3, Phase 1
22 Antimitotic Agents Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Alkylating Agents Phase 3,Phase 2,Phase 1
25 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
26 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 3,Phase 2,Phase 1
28 Antirheumatic Agents Phase 3,Phase 2,Phase 1
29 Etoposide phosphate Phase 3,Phase 2,Phase 1
30 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
31 Liver Extracts Phase 3,Phase 2,Phase 1
32 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
33 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
34 Antiviral Agents Phase 3,Phase 2,Phase 1
35 Gemtuzumab Phase 2, Phase 3
36 Adjuvants, Immunologic Phase 3,Phase 1,Phase 2
37 Antifungal Agents Phase 3,Phase 2,Phase 1
38 Antilymphocyte Serum Phase 3,Phase 2
39 Calcineurin Inhibitors Phase 3
40 Cyclosporins Phase 3
41 Dermatologic Agents Phase 3,Phase 2,Phase 1
42
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
43
Mesna Approved Phase 1, Phase 2 3375-50-6 598
44
Indinavir Approved Phase 2 150378-17-9 5362440
45
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
46
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
47
Acetaminophen Approved Phase 1, Phase 2 103-90-2 1983
48
Diphenhydramine Approved Phase 1, Phase 2 58-73-1, 147-24-0 3100
49
Histamine Approved, Investigational Phase 1, Phase 2 75614-87-8, 51-45-6 774
50
Promethazine Approved Phase 1, Phase 2 60-87-7 4927

Interventional clinical trials:

(show top 50) (show all 144)

id Name Status NCT ID Phase Drugs
1 Collaborative Wilms Tumour Africa Project Recruiting NCT01991652 Phase 4
2 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
3 WT1 for the Detection of Minimal Residual Disease Completed NCT00179829 Phase 2, Phase 3
4 Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Completed NCT00909168 Phase 2, Phase 3 FLAIMy - Fluda, Ida, Ara-C, Mylotarg
5 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
6 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
7 Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk Completed NCT00860639 Phase 3 gemtuzumab ozogamycin
8 A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old Completed NCT00927498 Phase 3 conventional chemotherapy (AraC + Daunorubicin),;Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
9 HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk Completed NCT02461121 Phase 3 cyclosporine A;Mycophenolate mofetil;Ara-C;fludarabine;anti-lymphocyte globulin;cyclophosphamide
10 Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Unknown status NCT01513109 Phase 1, Phase 2
11 WT1 Peptid Vaccination in Carcinomas Unknown status NCT00153608 Phase 2
12 WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) Unknown status NCT00153582 Phase 2
13 Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
14 Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma Unknown status NCT00965224 Phase 2
15 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
16 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
17 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
18 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
19 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor Completed NCT00001509 Phase 2 IFN-alpha with retinoic acid
20 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
21 Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers Completed NCT00488592 Phase 2 GM-CSF (Sargramostim)
22 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Completed NCT00923910 Phase 1, Phase 2 WT1 Peptide-Pulsed Dendritic Cells;Donor Lymphocytes;IL-4;KLH;WT1 Peptides;Endotoxin;Diphenhydramine;Acetaminophen
23 Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy Completed NCT01819558 Phase 1, Phase 2
24 Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
25 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
26 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy Completed NCT00433745 Phase 2 WT1 Peptide Vaccine
27 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Completed NCT00052520 Phase 1, Phase 2
28 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
29 To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Completed NCT01222780 Phase 1, Phase 2 Marqibo
30 Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies Completed NCT00038207 Phase 2 Liposomal Vincristine
31 Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD Completed NCT02027805 Phase 1, Phase 2
32 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
33 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
34 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
35 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
36 Pharmacokinetic Study of Doxorubicin in Children With Cancer Completed NCT01095926 Phase 2 doxorubicin
37 Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
38 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Completed NCT00309907 Phase 2 methylprednisolone
39 Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy Completed NCT00066599 Phase 2 voriconazole
40 Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer Completed NCT00003408 Phase 2
41 Ixabepilone in Treating Young Patients With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
42 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
43 Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors Completed NCT00365768 Phase 2 Glutamine
44 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2
45 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors Completed NCT00004157 Phase 2
46 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
47 Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00002673 Phase 2
48 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
49 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
50 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate

Search NIH Clinical Center for Wilms Tumor 2

Genetic Tests for Wilms Tumor 2

Genetic tests related to Wilms Tumor 2:

id Genetic test Affiliating Genes
1 Wilms Tumor 2 29

Anatomical Context for Wilms Tumor 2

MalaCards organs/tissues related to Wilms Tumor 2:

39
Myeloid, T Cells, Bone, Bone Marrow, Kidney, Lung, Liver

Publications for Wilms Tumor 2

Variations for Wilms Tumor 2

ClinVar genetic disease variations for Wilms Tumor 2:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 H19 H19, 5.3-KB DEL deletion Pathogenic
2 H19 H19, 1.43-KB TRIPLICATION undetermined variant Pathogenic
3 H19; H19-ICR; ICR1; MRPL23 NR_002196.1(H19): n.-7080_-1781del deletion Pathogenic GRCh38 Chromosome 11, 1999616: 2004919
4 H19; H19-ICR; ICR1; MRPL23 GRCh38/hg38 11p15.5(chr11: 2000799-2001783)x3 copy number gain Pathogenic GRCh37 Chromosome 11, 2022018: 2023452

Expression for Wilms Tumor 2

Search GEO for disease gene expression data for Wilms Tumor 2.

Pathways for Wilms Tumor 2

GO Terms for Wilms Tumor 2

Sources for Wilms Tumor 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....